Gene therapy trial linked to Chinese boy’s death showed limited benefit
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Published results from the first human trial of HuidaGene’s Shanghai-developed gene-editing therapy for Duchenne muscular dystrophy show it edited some target genes but offered limited therapeutic benefit. One of four treated children died from a catastrophic immune reaction; the firm announced the death on 5 August, roughly a year later, after criticism over delayed disclosure.
Continue in the app — vote & join in ➔Source: Nature News · via ahirlevel.hu